



بسم الله الرحمن الرحيم

∞∞∞∞

تم عمل المسح الضوئي لهذه الرسالة بواسطة / سامية زكى يوسف

بقسم التوثيق الإلكتروني بمركز الشبكات وتكنولوجيا المعلومات دون أدنى

مسئولية عن محتوى هذه الرسالة.

ملاحظات:

- بالرسالة صفحات لم ترد بالأصل
- بعض الصفحات الأصلية تالفة
- بالرسالة صفحات قد تكون مكررة
- بالرسالة صفحات قد يكون بها خطأ ترقيم

Role of Cytokines in Graft Versus Host Disease after Peripheral Blood Stem Cell Transplantation (PBSCT)

A thesis submitted for partial fulfillment of MD degree in clinical and
chemical pathology


Presented by
Dr. / Eman Kamal A. El Fattah
MB BCh /Msc

616,07561

Supervised by
Prof. Dr./Azza Mahmoud Kamel
Professor of clinical pathology Dept.
National Cancer Institute .Cairo University

Prof. Dr. /Hussam Mahmoud Kamel
Professor of medical oncology
National Cancer Institute .Cairo University

Consultant Dr. /Nahla Mohamed El Sharkawy
Consultant of clinical pathology
National Cancer Institute .Cairo University



National Cancer Institute
Cairo University
(2010)

محضر اجتماع لجنة الحكم

على الرسالة المقدمة من الطيبية / ايمان كمال عبدالفتاح سيد احمد
لدرجة الدكتوراة فى الباثولوجيا الاكلينيكية وتحليلات الامراض السرطانية

اجتمعت لجنة انحكم على الرسالة المذكورة من السادة /
الاستاذ الدكتور / عزة محمود كامل [عن المشرفين]
الاستاذ الدكتور / نادية محمد موافى [ممتحن خارجى]
الاستاذ الدكتور / مرفت الانصارى [ممتحن داخلى]

وذلك فى يوم الثلاثاء الموافق ٢٠١٠/٥/١١ فى الساعة الحادية عشر ظهراً فى
جلسة علنية بمدرج / قاعه المؤتمرات بالمعهد .

ثم ناقشه السادة أعضاء لجنة الحكم فى ~~الادلة والبراهين~~
~~من الطيبية ايمان كمال عبدالفتاح سيد~~

وقررت اللجنة
قبول الرسالة

الاستاذ الدكتور

ع.م.

الاستاذ الدكتور

ع.م.

الاستاذ الدكتور

ع.م.

This study showed statistically significant difference ($P < 0.05$) between the elevated level of IL10 and the absence of acute GVHD detected in post conditioning phase i.e. patient origin.

A cut off point of ≥ 1.13 pg/ml for IFN γ /IL10 ratio in culture supernatant showed a sensitivity of 85.7%, specificity of 83.3% and a total accuracy of 84.6% of predicting acute GVHD.

Key words: acute GVHD, cytokines.

Acknowledgment

First of all, great thanks to ALLAH.

I would like to express my deep gratitude to Prof. Dr. Azza Mahmoud Kamel, Professor of Clinical Pathology, National Cancer institute, Cairo University for her great scientific support from the beginning of the study until the end. I will always be proud to have worked under her guidance.

I also address my sincere thanks to consultant Dr. Nahla Mohammed Elsharkawy, consultant of clinical pathology, National Cancer institute, Cairo University, for her great effort and her helpful supervision.

I would also like to thank all my staff and my dear colleagues in the Clinical Pathology department, National Cancer institute, Cairo University, for their cooperation and kind support.

I would also love to express my deep love and gratitude to my dear father, mother and my family, without their prayers and support, this work would not have seen the light.

Title	Page
List of tables	II - IV
List of figures	V - VI
List of abbreviations	VII - VIII
Introduction and aim of work	1 - 3
Review of literature	4 - 106
Chapter 1: Hematopoietic Stem Cell Transplantation	4 - 22
Chapter 2: Cytokines	23 - 44
Chapter 3: Graft Versus Host Disease	45 - 106
Patients and methods	107 - 121
Results	122 - 177
Discussion	178 - 196
Conclusions and recommendations	197 - 199
Summary	200 - 203
References	204 - 245
Arabic summary	2 -1

Number	Title	Page
Table 1	Diseases commonly treated with hematopoietic stem cell transplantation	5
Table 2	Major cytokines, immune sources, principal targets and effects.	29
Table 3	Stages of acute GVHD.	86
Table 4	Stages of acute GVHD.	108
Table 5	Level of cytokines of donor's origin in cases who developed chronic GVHD	122
Table 6	Level of cytokines of patient's origin in cases who developed chronic GVHD	123
Table 7	IL 4 of donor's origin	125
Table 8	Level of IL 4 of patient's origin	125
Table 9	Level of IL 7 of patient's origin	126
Table 10	Level of IL 10 of donor's origin	127
Table 11	Level of IL 10 of patient's origin	128
Table 12	Level of IL 12 of donor's origin	129
Table 13	Level of IL 12 of patient's origin.	130
Table 14	Level of IFN γ of donor's origin	131
Table 15	Level of IFN γ of patient's origin	132

Number	Title	Page
Figure 1	Regulation of the JAK STAT signal transduction pathway.	28
Figure 2	Schematic representation of HLA class I and II molecules.	50
Figure 3	Luminex 2000 machine.	114
Figure 4	Polystyrene microspheres used for luminex machine.	115
Figure 5	Fluidics system of Luminex machine	116
Figure 6	The 2 lasers of the Luminex	117
Figure 7	Luminex detectors	118
Figure 8	Levels of IFN γ in relation to acute GVHD in culture supernatant of measured cases receiving HSCT from a sibling donor	136
Figure 9	Levels of IFN γ in relation to acute GVHD in post engraftment phase of measured cases receiving HSCT from a sibling donor	138
Figure 10	Levels of IL12 in relation to acute GVHD in culture supernatant of measured cases receiving HSCT from a sibling donor	139
Figure 11	Levels of IL12 in relation to acute GVHD in post engraftment phases of measured cases receiving HSCT from a sibling donor	141
Figure 12	Levels of IL10 in relation to acute GVHD in culture supernatant of measured cases receiving HSCT from a sibling donor.	143
Figure 13	Levels of IL10 in relation to acute GVHD in post engraftment phases of measured cases receiving HSCT from a sibling donor	145
Figure 14	Levels of IL4 in relation to acute GVHD in culture supernatant of measured cases receiving HSCT from a sibling donor	146
Figure 15	Level of IL4 in relation to acute GVHD in post engraftment phase of measured cases receiving HSCT from a sibling donor	148

Figure 1	Levels of IFN γ in relation to acute GVHD in post conditioning phase of measured cases receiving HSCT from a sibling donor	150
Figure 17	Levels of IFN γ in relation to acute GVHD in aplastic phase of measured cases receiving HSCT from a sibling donor	152
Figure 18	Levels of IL12 in relation to acute GVHD in post conditioning phase of measured cases receiving HSCT from a sibling donor.	154
Figure 19	Levels of IL12 in relation to acute GVHD in aplastic phase of measured cases receiving HSCT from a sibling donor.	15
Figure 20	Levels of IL10 in relation to acute GVHD in post conditioning phase of measured cases receiving HSCT from a sibling donor.	158
Figure 21	Levels of IL10 in relation to acute GVHD in aplastic phase of measured cases receiving HSCT from a sibling donor	159
Figure 22	Levels of IL4 in relation to acute GVHD in post conditioning phase of measured cases receiving HSCT from a sibling donor.	161
Figure 23	Levels of IL4 in relation to acute GVHD in aplastic phase of measured cases receiving HSCT from a sibling donor	163
Figure 24	Detectable levels of IL7 in post conditioning phase in cases who developed and those who did not develop acute GVHD	165
Figure 25	Level of IL7 in relation to acute GVHD in aplastic phase of measured cases receiving HSCT from a sibling donor.	166
Figure 26	Collective ROC curves for level of IFN γ , IL10, IL4 and IL12 in culture supernatant and IFN γ , and IL12 in post engraftment phase.	172
Figure 27	ROC curve for IFN γ / IL10 ratio in culture supernatant	176

Abbreviation	Full name
ADL	Activities of daily living
AIDS	Acquired immunodeficiency syndrome
APCs	Antigen presenting cells
ATG	Anti thymocyte globulin
ATP	Adenosine triphosphate
BMT	Bone Marrow Transplantation
cAMP	Cyclic adenosine monophosphate
CDKs	Cyclin dependent kinases
CD	Cluster of differentiation
CTLA	Cytotoxic T Lymphocyte associated antigen
CMV	Cytomegalovirus
CTLs	Cytotoxic T lymphocytes
CXCR4	CXC chemokine receptor 4
DCs	Dendritic Cells
DNA	Deoxyribonucleic acid
G CSF	Granulocyte Colony stimulating Factor
GM CSF	Granulocyte Macrophage colony stimulating factor
gp	glycoprotein
GVHD	Graft Versus Host Disease
GVL	Graft Versus Leukemia
HIV	Human immunodeficiency virus
HLA	Human Leucocyte Antigen
HSCs	Hematopoietic stem cells
HSCT	Haematopoietic stem cell transplantation
ICAM 1	Inter Cellular Adhesion Molecule 1
IFNs	Interferons
IFN α	Interferon α
IFN β	Interferon β
IFN γ	Interferon γ
IL1	Interleukin 1
IL2	Interleukin 2
IL3	Interleukin 3
IL4	Interleukin 4
IL5	Interleukin 5
IL6	Interleukin 6
IL7	Interleukin 7
IL7R	Interleukin 7 Receptor
IL8	Interleukin 8
IL9	Interleukin 9

IL10	Interleukin 10
IL11	Interleukin 11
IL12	Interleukin 12
IL12R	Interleukin 12 Receptor
IL13	Interleukin 13
IL14	Interleukin 14
IL15	Interleukin 15
IL16	Interleukin 16
IL17	Interleukin 17
IL18	Interleukin 18
IL21	Interleukin 21
IL22	Interleukin 22
IL23	Interleukin 23
IL27	Interleukin 27
JAK	Janus kinase
kDa	Kilo dalton
KIRs	Killer Inhibitory Receptors
LPS	Lipopolysaccharides
mAb	Monoclonal antibody
MCSF	Macrophage colony stimulating factor
MHC	major histocompatibility complex
miHAs	Minor histocompatibility antigens
MMF	Mycophenolate mofetil
mRNA	Messenger RNA
NIH	National Institutes of Health
NK	Natural Killer
ROS	Reactive oxygen species
RNA	Ribose Deoxyribonucleic Acid
SHP 1	Src homology 2 domain Phosphatase 1
STAT	Signal Transducer and Activator of Transcription
TCR	T cell receptor
TGF β	Transforming growth factor β
TGF β R	Transforming Growth Factor Receptor
TGF β R I	Transforming Growth Factor Receptor I
TGF β R II	Transforming Growth Factor Receptor II
Th 0	T helper 0
Th 1	T helper 1
Th 2	T helper 2
Th3	T helper 3
TLRs	Toll like receptors
TNF α	Tumor necrosing factor α
TNF β	Tumor necrosing factor β

TNF	Tumor necrosing factor
Tr	T regulatory
TRAIL	TNF related apoptosis inducing ligand
TRM	Transplantation related mortality
VOD	Veno Occlusive Disease
6MPD	methylprednisolone
